These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 19222378)
21. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068 [TBL] [Abstract][Full Text] [Related]
22. The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. Butt AJ; Sergio CM; Inman CK; Anderson LR; McNeil CM; Russell AJ; Nousch M; Preiss T; Biankin AV; Sutherland RL; Musgrove EA Breast Cancer Res; 2008; 10(2):R28. PubMed ID: 18373870 [TBL] [Abstract][Full Text] [Related]
23. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Frings O; Augsten M; Tobin NP; Carlson J; Paulsson J; Pena C; Olsson E; Veerla S; Bergh J; Ostman A; Sonnhammer EL Am J Pathol; 2013 Jun; 182(6):2037-47. PubMed ID: 23583284 [TBL] [Abstract][Full Text] [Related]
24. An empirical Bayes approach to inferring large-scale gene association networks. Schäfer J; Strimmer K Bioinformatics; 2005 Mar; 21(6):754-64. PubMed ID: 15479708 [TBL] [Abstract][Full Text] [Related]
25. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402 [TBL] [Abstract][Full Text] [Related]
26. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens]. Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248 [No Abstract] [Full Text] [Related]
27. Semiparametric Bayesian kernel survival model for evaluating pathway effects. Zhang L; Kim I Stat Methods Med Res; 2019; 28(10-11):3301-3317. PubMed ID: 30289021 [TBL] [Abstract][Full Text] [Related]
28. Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer. Du JX; Chen C; Luo YH; Cai JL; Cai CZ; Xu J; Ni XJ; Zhu W Gene; 2020 Dec; 762():144974. PubMed ID: 32707305 [TBL] [Abstract][Full Text] [Related]
29. Gene expression patterns associated with p53 status in breast cancer. Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101 [TBL] [Abstract][Full Text] [Related]
30. Nonfamilial breast cancer subtypes. Ringnér M; Staaf J; Jönsson G Methods Mol Biol; 2013; 973():279-95. PubMed ID: 23412797 [TBL] [Abstract][Full Text] [Related]
31. Missing-value estimation using linear and non-linear regression with Bayesian gene selection. Zhou X; Wang X; Dougherty ER Bioinformatics; 2003 Nov; 19(17):2302-7. PubMed ID: 14630659 [TBL] [Abstract][Full Text] [Related]
32. Using Bayesian networks to analyze expression data. Friedman N; Linial M; Nachman I; Pe'er D J Comput Biol; 2000; 7(3-4):601-20. PubMed ID: 11108481 [TBL] [Abstract][Full Text] [Related]
33. Using graphical models and genomic expression data to statistically validate models of genetic regulatory networks. Hartemink AJ; Gifford DK; Jaakkola TS; Young RA Pac Symp Biocomput; 2001; ():422-33. PubMed ID: 11262961 [TBL] [Abstract][Full Text] [Related]
34. Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients. Fan M; Xia P; Liu B; Zhang L; Wang Y; Gao X; Li L Breast Cancer Res; 2019 Oct; 21(1):112. PubMed ID: 31623683 [TBL] [Abstract][Full Text] [Related]
35. MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets. Lemieux S; Sargeant T; Laperrière D; Ismail H; Boucher G; Rozendaal M; Lavallée VP; Ashton-Beaucage D; Wilhelm B; Hébert J; Hilton DJ; Mader S; Sauvageau G Nucleic Acids Res; 2017 Jul; 45(13):e122. PubMed ID: 28472340 [TBL] [Abstract][Full Text] [Related]
36. Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Fujiwara K; Yuwanita I; Hollern DP; Andrechek ER Cancer Res; 2011 Mar; 71(5):1924-32. PubMed ID: 21245101 [TBL] [Abstract][Full Text] [Related]
37. Sparse multivariate factor analysis regression models and its applications to integrative genomics analysis. Zhou Y; Wang P; Wang X; Zhu J; Song PX Genet Epidemiol; 2017 Jan; 41(1):70-80. PubMed ID: 27862229 [TBL] [Abstract][Full Text] [Related]
38. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834 [TBL] [Abstract][Full Text] [Related]